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Abstract
Background: The MexTAg transgenic mouse model of mesothelioma replicates many aspects of human mesothelioma,
including induction by asbestos, pathogenicity and response to cytotoxic chemotherapy, despite high levels of the SV40
large T Antigen (TAg) in the mesothelial compartment. This model enables analysis of the molecular events associated
with asbestos induced mesothelioma and is utilised here to investigate the molecular dynamics of tumours induced in
these mice, using gene expression patterns as a read out.
Methods: Gene expression of MexTAg mesothelioma cell lines bearing a high or low number of copies of the TAg
transgene were compared to wild type mouse mesotheliomas and normal mouse mesothelial cells using Affymetrix
microarray. These data were then compared to a similar published human microarray study using the same platform.
Results: The main expression differences between transgenic mouse and wild type mouse mesotheliomas occurred for
genes involved in cell cycle regulation and DNA replication, as would be expected from overexpression of
the TAg oncogene. Quantitative PCR confirmed that E2F and E2F regulated genes were significantly more
upregulated in MexTAg mesotheliomas and MexTAg mesothelial cells compared to wild type mesotheliomas.
Like human mesothelioma, both MexTAg and wild type mesotheliomas had more genes underexpressed than
overexpressed compared to normal mouse mesothelial cells. Most notably, the cdkn2 locus was deleted in
the wild type mouse mesotheliomas, consistent with 80 % human mesotheliomas, however, this region was
not deleted in MexTAg mesotheliomas. Regardless of the presence of TAg, all mouse mesotheliomas had a
highly concordant set of deregulated genes compared to normal mesothelial cells that overlapped with the
deregulated genes between human mesotheliomas and mesothelial cells.
Conclusions: This investigation demonstrates that the MexTAg mesotheliomas are comparable with wild type
mouse mesotheliomas in their representation of human mesothelioma at the molecular level, with some key
gene expression differences that are attributable to the TAg transgene expression. Of particular note, MexTAg
mesothelioma development was not dependent on cdkn2 deletion.
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Background
Malignant mesothelioma is an aggressive tumour arising
from the mesothelial cells lining the pleura, peritoneum
or pericardium. The principal carcinogen associated with
malignant mesothelioma is asbestos and several epi-
demiological data sets and clinical evidence have con-
firmed its carcinogenic properties [1]. This tumour is a
major problem due to its increasing incidence and the
lack of effective treatments [2, 3]. Asbestos induces a
similar tumour in mice to that seen in humans [4]. This
has enabled the transplantation of asbestos-induced
mesothelioma into syngeneic mice and has provided
useful preclinical information that has guided novel clin-
ical trials [5]. However such models rely on transplant-
ation of clonal tumour cell lines rather than tumours
being induced in situ by asbestos. These models also
suffer from a lack of accurate molecular definition,
restricting our capacity to study molecularly targeted
therapies [1].
To overcome these limitations we created a murine
mesothelioma model in which mesothelioma is reliably in-
duced by the natural carcinogen, asbestos. We achieved
this by generating transgenic mice in which the Simian
Virus 40 (SV40) large T antigen (TAg) is expressed under
the control of the tissue specific mesothelin promoter [6].
In this system, mesothelioma rapidly and reproducibly de-
velops in the peritoneum after instillation of asbestos [7].
Thus, the model represents an anatomically relevant loca-
tion for mesothelioma and its emergence from mesothelial
cells, as well as tumour induction by the known carcino-
gen. This presented an ideal opportunity to analyse the
molecular events associated with asbestos induced meso-
thelioma. We therefore utilised this system to analyse the
molecular dynamics of tumours arising in mice fol-
lowing asbestos exposure, using gene expression pat-
terns as a readout.
At a molecular level mesothelioma is characterised by
genetic loss and loss of function of tumour suppressor
genes; most commonly cdkn2a and b (encoding p16,
p15 and p14 cyclin dependent kinase inhibitor genes);
NF2 (neurofibromatosis gene), BAP-1 (BRAC-1 associ-
ated protein, an ubiquitase) and LATS-2 [8–10]. Muta-
tions in the tumour suppressors p53 and retinoblastoma
(RB) family and the oncogenic ras family occur at a con-
siderably lower frequency in mesothelioma compared to
other cancer types [11].
SV40 has been utilized to generate transgenic murine
models of various cancer types. In most cases the early
coding region of SV40 is targeted to the cell type of
interest using a specific promoter, for example the RIP-
TAG model of pancreatic cancer uses the rat insulin
promoter and the TRAMP model of prostate cancer uses
the probasin promoter [12–14]. Malignant transformation
in these mice results primarily from the inactivation of the
tumour suppressors p53 and RB following binding to TAg
[15]. The loss of p53 function makes cells less susceptible
to apoptosis [16]. Inactivation of RB results in the activa-
tion of the E2F family of transcription factors that induce
cell cycle-promoting genes [17]. In the majority of SV40
TAg cancer models, mice develop tumours as they age,
for example 100 % of TRAMP mice develop poorly differ-
entiated pancreatic adenocarcinomas by 24 weeks of age
[13]. Furthermore, in TRAMP mice the mutation rate is
much lower than for carcinogen-induced tumours [18].
Not only does the MexTAg model of mesothelioma devel-
opment have a strict requirement for the relevant carcino-
gen, asbestos but a key distinction from other transgenic
mesothelioma models, is that interfering spontaneous tu-
mours do not develop in the peritoneum or pleura in the
absence of the carcinogen [19].
Three MexTAg mouse lines were developed with dif-
ferent copy numbers of the TAg transgene inserted into
the mouse genome [7]. The lines, denoted high TAg
(hiTAg), intermediate TAg (intTAg) and single TAg
(sTAg) have 100, 32 or single copy of the TAg transgene,
respectively. All of the high copy MexTAg mice rapidly
develop mesothelioma after asbestos exposure compared
to approximately 20–30 % of wild-type mice which de-
velop mesothelioma over a much longer time span [7].
The rate of mesothelioma development is TAg dose
dependent: intTAgMexTAg mice have a slower rate than
hiTAg mice and the single copy sTAg MexTAg mice
have a similar rate to that of wild type mice, and inci-
dence was found to be 90 and 83 % in intTAg and sTAg
mice respectively [7]. However, the time to progression
after diagnosis is similar between the four models [20].
This suggests that TAg has a role in disease initiation,
but that the further development of the mesothelioma is
not affected by the presence of TAg. Indeed, MexTAg
mesotheliomas respond to cytotoxic chemotherapy in
the same way as wild-type mice and patients with meso-
theliomas [20].
This study was undertaken to investigate the gene ex-
pression differences between wild type and TAg express-
ing mouse mesotheliomas, to examine the relationship
between these models and with human mesothelioma,
and in the process to identify gene expression patterns




Experimental mice were housed in an approved facility,
under Animal Ethics Committee approved conditions.
Breeding colonies of MexTAg transgenic mice were
maintained at The Biomedical Research Facility, Univer-
sity of Western Australia, Perth. Three MexTAg lines
were used; the MexTAg 299 h line which has 100 copies
Robinson et al. BMC Cancer  (2015) 15:983 Page 2 of 14
of the TAg transgene (hiTAg); the MexTAg 304i line with
32 copies of the transgene (intTAg); and MexTAg 266 s
with a single copy (sTAg) [7]. The genotype of each mouse
was confirmed by PCR with DNA from murine tails as de-
scribed previously [7]. C57Bl/6 J wild type mice were pur-
chased from Animal Resources Centre, Perth WA. All
animal work was carried out under NHMRC guidelines
and with approval from the University of Western Australia
Animal Ethics Committee.
Cell lines
For summary of cell line nomenclature, refer to Table 1.
Normal mesothelial cell preparation
Peritoneum of wild type C57Bl/6 J mice or TAg trans-
genic mice were surgically resected and aseptically cut
into small pieces. Mesothelial cells were removed from
peritoneum by incubating in 5 ml trypsin (0.25 % in
EDTA buffer; Gibco) for 30 min at 37 °C, with gentle
agitation. The peritoneum was then discarded and cells
were pelleted and cultured in tissue culture flasks in
RPMI 1640 medium containing 10 % FCS (Invitrogen),
supplemented with 100 U/mL penicillin, 100 μg/mL
streptomycin, 2 mM L-glutamine (Gibco). Cells were
passaged 2 or 3 times at a ratio of 1:2 or 1:3 prior to
preparation of the RNA for the array.
Mouse mesothelioma cell preparation
Mice were injected with 6 mg of asbestos (IUCC refer-
ence sample of Wittenoom Gorge crocidolite) intraperi-
toneally and euthanized when symptoms of disease were
evident, as described previously [7]. At endpoint mice
were euthanized and ascites fluid was collected under
sterile conditions. Ascites fluid was placed in tissue cul-
ture flasks with 10× volume of RPMI (Life Technologies)
supplemented with 10 % FCS (Invitrogen, Life Tech-
nologies), under 5 % CO2 and 95 % humidity. Cell lines
were characterised and confirmed to be mesothelioma
by electron microscopy, carried out at Anatomical
Pathology, PathWest Laboratory Medicine, QEII Medical
Centre, Perth WA. Cells were passaged as required.
Microarray sample preparation and hybridization
Microarray experiments were performed at the Peter
MacCallum Cancer Centre, East Melbourne, Australia).
Total RNA was extracted from cells at low passage num-
ber, as described in Table 1, using TRIZOL reagent (Life
Technologies) and further purified by column chromatog-
raphy using a Qiagen RNeasy spin column (Qiagen). RNA
quality and quantity was confirmed using the Agilent
2100 Bioanalyzer and the RNA 6000 Nano Assay kit (Agi-
lent Biotechnologies, Palo Alto, CA). RNA was profiled
according to the manufacturer’s protocols on Affymetrix
Mouse Genome 430 V2 GeneChips (Affymetrix, Santa
Clara CA), which cover approximately 39,000 transcripts.
Data was extracted and processed using GeneChip Oper-
ating Software (Affymetrix) and gene expression data
(*.cel files) were loaded into ‘R’ statistical package [21]. All
of the resulting gene expression data (*.cel files) were
retained after expression quality was analysed using the
QCReport function from the affyQCReport library.
Table 1 Cell line and tumour sample nomenclature and information




WTtu C57Bl/6 J Wild type
mesothelioma
None 6 5.5 (3–8)
WTn C57Bl/6 J Normal mesothelial
cells
None 2 3.5 (3–4)
sTAgtu MexTAg
transgenic
TAg mesothelioma Single copy 3 3 (2–6)
intTAgtu MexTAg
transgenic
TAg mesothelioma Intermediate copy (32) 3 2 (2–4)
loTAgtua MexTAg
transgenic
TAg mesothelioma Combined single and intermediate copy
tumour samples
(6) As above 2 rows
hiTAgtu MexTAg
transgenic





High copy (100) 2 3 (3–4)
Htub Human Primary tissue - 5 cases n/a
Hnb Human Non malignant tissue - 6 cases n/a
Footnotes
n indicates normal mesothelial cells, tu indicates a malignant mesothelioma cell line
adata set is a combination of sTAGtu and intTAgtu, therefore not in cluster analysis (see Results section)
bRoe et al. [22]
Robinson et al. BMC Cancer  (2015) 15:983 Page 3 of 14
Human microarray data
Microarray expression data for human mesothelioma was
previously described by Roe et al., [22] and E-MTAB-47
data set available from the ArrayExpress http://www.ebi.a-
c.uk/arrayexpress/ database. Briefly, Affymetrix Human
Genome U133 Plus 2.0 GeneChip data was available for 5
mesothelioma patients and normal parietal and visceral
pleural samples from six non-cancer patients. There were
18 samples from 11 patients. One was rejected on the
grounds of quality control, based on data from the R func-
tion QCReport and fitPLM, suggestive of hybridisation
anomalies. Of the remaining 17 experiments, 6 are meso-
thelioma samples and 11 are controls.
Microarray data analysis
The raw probe set intensities were normalised by the
GC robust multi-array average function (gcrma). Data
were clustered using the program Cluster and visualised
using the program TreeView. Differential gene expres-
sion between groups was determined using the make-
Contrasts and contrasts.fit functions from the linear
models for microarray data (limma) package, with the
empirical Bayes function eBayes used to assess the sig-
nificance and Benjamini and Hochberg False Discovery
Rate corrected p-values reported. A p-value ≤ 0.05 was
considered significant. Probe lists were collapsed to gene
lists using a Python program based on the annotation
files for the Human Genome U133 Plus 2.0 GeneChip
provided by Affymetrix (Release 33), with the gene as-
sumed to be represented by the most significant probe.
Lists of significant genes were tested for over representa-
tion in KEGG pathways [23, 24]. P-values were corrected
for multiple comparisons and pathways exhibiting cor-
rected P-values of less than 0.05 were considered sig-
nificant. Murine genes were mapped to their human
homologues using a purpose written Python program
using data from the database, HOM_AllOrganism.rpt,
available from the Jackson Laboratory (ftp://ftp.informa-
tics.jax.org/pub/reports/HOM_All Organism.rpt). The raw
probe set intensities were normalised by the GC robust
multi-array average function (gcrma) of the linear models
for microarray data (Limma) package [25]. The Limma
volcano plot function was used to plot log-fold change
of individual probe-sets versus log-odds of the differen-
tial expression calculated above between the groups.
Array data can be accessed through ArrayExpress ac-
cession number: E-MTAB-3988.
PCR
RNA was extracted from 1 × 107 cultured cells or 100 mg
mouse tissues using TRIZOL reagent (Invitrogen) accord-
ing to manufacturer’s instructions. 5 μg RNA was reverse
transcribed into cDNA using Omniscript (Qiagen) accord-
ing to manufacturer’s instructions. PCR was performed
with cDNA using forward and reverse primers as de-
scribed in Additional file 1: Table S1, using optimised con-
ditions based on the following: 95 °C 5mins, 35 cycles of
95 °C, 60 °C, 72 °C for 30 s at each temperature, followed
by a final extension of 5 mins at 72 °C. Relative amounts
of the transcripts were normalised to GAPDH transcript
in the same cDNA samples.
Results
Hierarchical clustering by gene expression segregate
MexTAg and wild type mesothelioma
Mesotheliomas were induced in MexTAg transgenic and
wild type mice by asbestos instillation into the periton-
eum as described previously [7]. Cell lines were gener-
ated from the ascites of individual mice and gene
expression profiling was carried out on early passage
cells. Non-malignant mesothelial cell cultures were also
analysed. Details and nomenclature of samples is sum-
marized in Table 1. Unsupervised hierarchical clustering
analysis was performed using the entire gene set of ex-
pression profiles for a total of 22 samples. The resultant
dendrogram shows that the first division separates nor-
mal mesothelial cells derived from wild type mice from
the wild type mesotheliomas and all samples from TAg
transgenic mice (Fig. 1a).
One sample from an intermediate TAg copy number
MexTAg tumour cell line (denoted intTAgtu) appeared
to be an outlier because it segregated with normal meso-
thelial cells. However, the large difference in height of
the dendrogram arms at the point of segregation for
these samples, indicates they have substantially different
expression patterns.
The second major division separates both non-malignant
mesothelial cells and mesotheliomas from high copy trans-
genic mouse (hiTAgn and hiTAgtu) from the wild type
(WTtu), single TAg (sTAgtu) and intermediate TAg
(intTAgtu) tumors. Furthermore, two of the three single
copy TAg tumours branched more closely with wild type
tumour than with the intermediate copy TAg tumours.
This suggests that for high copy MexTAg mice, high TAg
expression imparts a stronger influence on gene expression
than malignancy.
The intermediate and single copy TAg tumours each
had only 3 independent profiles, compared to the 6
hiTAgtu arrays. Therefore we investigated the validity of
combining expression patterns of these samples in the
context of gene expression differences versus wild type
normal mesothelial cells (WTn). We found that 2846
probes were differentially expressed in the single TAg
experiment versus WTn, and 2899 probes were differen-
tially expressed in the intermediate TAgtu experiments
versus WTn, but there was an overlap of 2087 probes.
This amounted to 73 and 75 % for sTAgtu_versus WTn
and intTAgtu versus WTn, respectively. This supports
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the notion that combining sTAgtu and intTAgtu sam-
ples, to form a common study set is justified. This is de-
noted loTAgtu and consists of 6 samples.
HiTAg mesotheliomas have higher expression of cell cycle
regulatory genes compared to wild type mesotheliomas
Comparing the hiTAgtu and WTtu samples, 714 genes
were differentially expressed (adjusted p value < 0.05). Of
these 465 were overexpressed and 245 genes were
underexpressed (hiTAgtu:WTtu, Additional file 2: Table
S2). Cyclin dependent kinase inhibitor 2a and 2b
(CdkN2a and 2b), p107 and N-ras were all significantly
over-expressed in TAg tumours relative to wild type
tumours. In the loTAg tumours expression of the top 20
of these overexpressed genes were at levels intermediate
between hiTAg and WT tumours (Fig. 1b).
Pathway enrichment analysis [24] suggested that dif-
ferentially expressed genes were associated with cell
cycle control and DNA replication, which could be a
direct result of the TAg oncogene interaction with
cell cycle regulatory proteins (Table 2) Of note, there
was enrichment for the MAPK signaling pathway,
several genes in the pathway were overexpressed in
hiTAgtu but these did not include any of the MAP
kinases themselves. Thus suggesting a pathway more
favoured by the TAg tumours.
Fig. 1 a Dendrogram depicting unsupervised clustering of array data for 6 WTtu, 6 hiTAgtu, 3 intTAgtu and 3 sTAgtu together with 2 samples
from normal mesothelial cells from wild type mice (WTn) and 2 from high copy MexTAg mice (hiTAgn). b Expression of the top 20 most
significantly overexpressed genes in a comparison hiTAgtu and WTtu, in WTtu, hiTAgtu and loTAgtu samples
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Differentially expressed genes are more associated with
underexpression in asbestos-induced mouse mesothelio-
mas compared to normal mesothelial cells, regardless of
large T Antigen expression
Volcano plots were used to illustrate the expression
differences of all probes on the array between all
three asbestos-induced mesothelioma tumour types
and wild type normal mesothelial cells (Fig. 2a, b, c).
A similar pattern of over and under expression of
probes is seen for each comparison, with a higher
number of probes underexpressed than overex-
pressed in each case. The level of over and under
expression is also within a similar range for each
comparison. Comparing probe set differences be-
tween hiTAgtu and loTAgtu, revealed far less vari-
ation in fold change and there was an equal
distribution of under and overexpressed probes
(Fig. 2d).
Next we looked at the genes that were differentially
expressed between each tumour set (ie. tumours gener-
ated in wild-type, low or high copy TAg transgenic mice)
and normal mesothelial cells, and again found a greater
number of genes underexpressed than were overex-
pressed when compared to normal mesothelial cells.
There were 2203 genes differentially expressed be-
tween the asbestos induced wild type tumours (WTtu)
and normal mesothelial cells (WTn); 966 genes were sig-
nificantly overexpressed and 1236 were underexpressed
in the WTtu. Cdkn2a (encoding p16) was one of the
most significantly under-expressed genes. There was no
difference in expression between WTtu and WTn for
three other genes commonly deleted in human meso-
thelioma: Nf2, Bap1 and Lats2. However, as the fre-
quency of deletion of these genes is around 20–50 % of
human mesotheliomas, we would not logically expect to
find a deletion in the sample size of 6 tumours used in
this study.
A comparison of the MexTAg mesotheliomas with
normal mesothelial cells from wild type mice (WTn),
gave a similar number of genes with expression
differences: 2985 genes were differentially expressed be-
tween high copy MexTAg tumours (hiTAgtu) and nor-
mal mesothelial cells from wild type mouse (WTn)
tumours; 1364 genes were overexpressed and 1621
underexpressed.
In a comparison between low copy MexTAg tumours
(loTAgtu) and WTn samples, 3126 genes were differen-
tially expressed. Of these, 1301 genes were overex-
pressed and 1825 genes underexpressed.
A common set of genes is differentially expressed in
asbestos-induced tumours compared to normal mesothe-
lial cells
Comparison of the genes that were differentially
expressed between asbestos induced tumours in either
wild type or high copy SV40 TAg transgenic mice and
normal mesothelial cells revealed that over 80 % of the
genes were common to both models (Fig. 3a). A similar
overlap was observed comparing the gene lists differen-
tially expressed between the wild-type tumours and the
loTAg tumours (Fig. 3b). The top 20 most significantly
differentially expressed genes for each comparison was
highly concordant (Table 3). Genes commonly differen-
tially expressed in the asbestos-induced tumours in-
cluded known cancer and mesothelioma associated
genes such as the Aurora kinases A and B, survivin,
BRCA1, thymidine kinase, thymidylate synthase, eight
members of the mini-chromosome maintenance protein
family and topoisomerase 2 alpha (Additional file 3:
Table S3). Pathway analysis revealed significant enrich-
ment in these common sets of genes for the DNA repli-
cation and cell cycle control pathways (Table 4).
P16, but not other genes commonly deleted in human
mesothelioma, is deleted in the wild type mesotheliomas
but not in the hiTAg mesotheliomas
It was noted earlier that p16 expression levels were
higher in TAg tumours and TAg mesothelial cells
compared to wild type mesotheliomas, due to deletion
of the cdkN2A locus in the latter samples. Thus the
expression of the other genes commonly deleted in
human mesothelioma, NF2, BAP1 and LATS2 was in-
vestigated. However, these three genes were found at
similar levels in all three mouse tumour models as
well as the normal mesothelial cell lines from wild-
type or transgenic mice (Fig. 4). In addition, the ex-
pression of Rb was not significantly different between
the TAg transgenic and wild-type mouse samples:
even though TAg is known to bind and inactivate the
RB tumour suppressor gene, this regulation princi-
pally occurs by phosphorylation, rather than changes
in expression levels. No difference in expression level
of a non-TAg targeted or mesothelioma specific cyclin
Table 2 Pathway enrichment analysis for differentially
expressed genes between hiTAgtu and WTtu
Pathway p-value
G1 to S cell cycle control 3.27E-09
Cell cycle 6.93E–08
mRNA processing 9.94E–08
MAPK signalling pathway 1.39E–06
DNA Replication 1.49E–06
Cytoplasmic Ribosomal Proteins 6.98E–05
One carbon metabolism and related 8.94E–04
Protein–protein interactions in the podocyte 0.001066
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dependent kinase inhibitor, p21, was observed across
the sample set.
E2F targets are overexpressed in TAg tumours and TAg
mesothelial cells compared to wild type counterparts
The Rb family of proteins influence cell proliferation prin-
cipally through the actions of the E2F family of transcrip-
tion factors [17]. Thus, as TAg is known to inhibit and
bind Rb and RB family proteins [15], the effect of TAg ex-
pression on E2f and E2f targets, was investigated. Seven of
the eight E2f targets examined had increased expression
levels in the normal mesothelial cells from TAg transgenic
mice compared to those from wild-type mice (Fig. 5).
Whilst not significant there was also a trend for E2f levels
to be increased in normal mesothelial cells from TAg
transgenic mice relative to wild type.
Cell cycle pathway genes E2f, Rbl1 (p107), Ccne1 (cyc-
lin E) and cdk2, and DNA synthesis and replication
pathway genes, PCNA (proliferating cell nuclear antigen)
and DHFR (dihydrofolate reductase) had significantly
higher expression in the hiTAgtu samples compared to
WTtu (Fig. 5). However, thymidylate synthase (Tyms)
and thymidine kinase (TK1) were not significantly differ-
ent between TAg positive and WT tumours.
Fig. 2 Volcano plots of log-fold change versus log-odds of the differential probe-set expression showing comparative expression levels between
sample groups. a WTtu and WTn (b) hiTAgtu and WTn, (c) loTAgtu and WTn and (d) loTAgtu and HiTAgtu
Robinson et al. BMC Cancer  (2015) 15:983 Page 7 of 14
The three mouse mesothelioma models deregulate a
common set of genes that is also deregulated in human
mesothelioma
A comparison of human mesothelioma with normal hu-
man mesothelial cells of the pleura found 1809 differen-
tially expressed genes (Additional file 4: Table S4). Of
these, 1106 were overexpressed and 703 were underex-
pressed. Genes involved in cell cycle, mitosis, replication,
DNA repair and anti-apoptosis were overexpressed.
However, in this sample set there was no difference in
the expression of p16, NF2, BAP1 or LATS2.
Of the genes in the list of 1809 differentially expressed
human mesothelioma genes, 1645 had mouse orthologs.
A comparison of the 2203 differentially expressed genes
in mesotheliomas from wild type mice versus wild type
normal, with this 1645 gene set, found 284 common
Fig. 3 Proportional Venn diagram indicating the number of genes that are common to both sets of differentially expressed gene comparisons (a)
HiTAgtu_WTn and WTtu_WTn, (b) loTAgtu_WTn and WTtu_WTn
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genes (Fig. 6). Of these 284 wild type mouse to human
mesothelioma common genes, 91 % were also in the
hiTAgtu to human overlap and 90 % were in the
loTAgtu to human overlap (Fig. 6). There were 211
genes significantly differentially expressed common to
all 3 mouse models (Additional file 5: Table S5). These
211 genes have functional roles in cell cycle pathway,
DNA replication, G1-S phase transition and homologous
recombination (Table 5, Additional file 5: Table S5).
Gene expression differences identified in the MexTAg
cell lines had a greater level of overlap with the differen-
tially expressed genes expression in human mesothelio-
mas, versus their respective (wild type) normal
mesothelial cells: 374 genes for the loTAgtu and 359
genes for the hiTAgtu experiments.
Discussion
We have previously demonstrated that the pathogenesis
of mesothelioma in MexTAg transgenic mice exposed to
asbestos closely replicates human mesothelioma and it is
probably the same disease [19, 20]. While there are a
number of other mouse models of mesothelioma avail-
able, including transplantation and genetically engi-
neered models, these have a number of disadvantages
that render them less suitable as a model or for a mo-
lecular study such as this one. Transplantation models
are typically in an anatomically irrelevant site making
them less suitable for testing novel therapies. A number
of genetically engineered models have been generated,
such as the Nf2 or p16 knock out mice and Nf2.p53
hemizygous mice [19]. These mice do develop meso-
thelioma after asbestos exposure, but they are hindered
by spontaneous growth of other tumour types. That the
MexTAg model is absolutely dependent on asbestos for
disease induction and that mesotheliomas are the only
cancer to develop, makes this system unique amongst
cancer models.
In the current study we showed that the introduc-
tion of approximately 100 copies of large TAg into
murine mesothelial cells induces a change in the pat-
tern of overall gene expression that sees derived cell
lines cluster with the malignant rather than benign
mesothelial cells. Such transgenic mesothelial cells ex-
hibit some transformed properties [7] and are able to
grow when transplanted into syngeneic mice (unpub-
lished data, [26]. The segregation of mesothelioma
tumour cell lines from transgenic mice with low or
intermediate numbers of the transgene (loTAgtu and
sTAgtu) more closely with mesotheliomas from wild
type mice (WTtu) than those that develop in the high
copy MexTAg mice (hiTAgtu), suggests the molecular
differences caused by the presence of TAg are minor
Table 3 Top 20 genes most significantly differentially expressed in each tumour sample set compared to wild type normal
mesothelial cells
hiTAgtu_WTn WTtu_WTn loTAgtu_WTn Description
1 Kcna1 Kcna1 Kcna1 Potassium voltage-gated channel, shaker-related subfamily, member 1
2 Prl3a1 Prl3a1 Prl3a1 Prolactin family 3, subfamily a, member 1
3 Kcnc4 Kcnc4 Kcnc4 Potassium voltage gated channel, Shaw-related subfamily, member 4
4 Il17re Il17re Il17re Interleukin 17 receptor E
5 Srd5a2 Srd5a2 Srd5a2 Steroid 5 alpha-reductase 2
6 Prokr2 Prokr2 Prokr2 Prokineticin receptor 2
7 Chi3l1 Chi3l1 Chi3l1 Chitinase 3-like 1
8 Lnx1 Lnx1 Lnx1 Ligand of numb-protein X 1
9 Cmah Cmah Cmah Cytidine monophospho-N-acetylneuraminic acid hydroxylase
10 Emcn Ppp6r2 Ppp6r2 Endomucin //
11 Dmrtc1a Emcn Emcn DMRT-like family C1a
12 Ppp6r2 Dmrtc1a Dmrtc1a Protein phosphatase 6, regulatory subunit 2
13 Cldn10 Cldn10 Cldn10 Claudin 10
14 Selp Selp Selp Selectin, platelet
15 Myo5b Myo5b Myo5b Myosin VB
16 Tmem125 Tmem125 Tmem125 Transmembrane protein 125
17 Slc39a4 Slc39a4 Slc39a4 Solute carrier family 39 (zinc transporter), member 4
18 Fhit Fhit Fhit Fragile histidine triad gene
19 Eef1a2 Sox6 Sox6 Eukaryotic translation elongation factor 1 alpha 2
20 Sox6 Fam19a2 Fam19a2 SRY-box containing gene 6
Robinson et al. BMC Cancer  (2015) 15:983 Page 9 of 14
in comparison with the molecular changes that occur
as a result of tumorigenesis.
A comparison of the wild type and TAg transgenic tu-
mours showed that a common set of around 1800 genes
were differentially expressed compared to wild type nor-
mal mesothelial cells, regardless of TAg copy number.
However, the magnitude of difference in gene expression
levels was directly related to the TAg burden, suggesting
a TAg dose dependent affect. This is consistent with the
TAg dose dependent rate of induction of mesothelioma
by asbestos [7]. The differentially expressed genes we
identified are known to be involved in DNA replication
and cell cycle control, which could reflect either the in-
creased proliferation rate of tumours or a shared path-
way of gene expression changes that occur during
tumourigenesis. However, to our knowledge, this is the
first study to compare gene expression in a SV40TAg
murine cancer model with the same carcinogen induced
tumour in both wild type mice and humans. Previous
studies of SV40TAg murine cancer models have typically
compared gene expression differences with the human
cancer counterpart alone. Thus this is a unique study,
enabled by the properties of the model itself.
In all six of the wild type mouse mesotheliomas exam-
ined p16 was not expressed (above background levels).
This is reflective of human mesothelioma whereby dele-
tion of the cdkn2 locus on chromosome 9p21.3 encod-
ing the cyclin dependent kinase inhibitors p16 and p15
is common (up to 80 % of mesothelioma cases) and is
thought to be a primary driver of mesothelioma develop-
ment. Loss of p16 leads to an inability of the cell to
phosphorylate RB and activation of the E2F family of
transcription factors and increased cell proliferation. Of
note, p16 was expressed in all the MexTAg cell lines to a
similar level seen in normal wild type mesothelial cells.
However, no obvious changes in expression of other
genes frequently altered in human mesothelioma such as
NF2 and BAP1 was observed in MexTAg tumours. Con-
sistent with the known mechanisms through which TAg
exerts its oncogenic effect, TAg expressing cell lines had
significantly altered expression of genes downstream of
the tumour suppressors p53 and Rb family, including
E2F and E2F regulated genes. Thus implying the changes
in gene expression observed in the TAg positive meso-
theliomas mimic deletion of p16.
For mesotheliomas to develop in MexTAg mice the
addition of asbestos is essential. The similarities of Mex-
TAg mesotheliomas at both molecular and functional
levels with WT mouse mesotheliomas and their lack of
dependence on deletion of p16, suggests that additional,
as yet unidentified, genetic changes are required down-
stream of p16 loss for mesothelioma development. This
may be reflective of the multi-step hypothesis of tumour
development, for example, where a pattern of hyperpla-
sia, then dysplasia occurs before tumour formation. This
hypothesis may explain why tumours develop more rap-
idly following asbestos exposure in TAg expressing com-
pared to wild type mice and why the rate and incidence
of tumour development reflects the TAg transgene dose.
Also such a hypothesis explains why there is no differ-
ence in the rate or pattern of tumour progression seen
between MexTAg and wild type mesothelioma [20].
We made a comparison with a human data set that
was selected because it had been analysed on the same
platform as our mouse data. Although this comparison
was not optimal, due to a number of features, including
the fact that pleural as opposed to peritoneal mesotheli-
omas were compared, it did demonstrate that each of
the 3 mouse models had almost identical gene differ-
ences in common with the human study. Thus, wild type
and TAg transgenic mouse systems could be considered
equally good representations of human mesothelioma.
Given that the molecular consequences of TAg onco-
gene expression are well understood, together with our
Table 4 Top 10 significantly enriched pathways found in genes commonly differentially expressed between WTtu_WTn and i)
hiTAgtu_WTn or ii) loTAgtu_WTn
Pathway i) hiTAgtu and WTtu ii) loTAgtu and WTtu
p-value p-value
Cell cycle 0.0 0.0
G1 to S cell cycle control 0.0 0.0
DNA replication 1.760E–29 0.0
Mismatch repair 3.287E–9 1.59E–09
Homologous recombination 2.520E–6 4.66E–05
Purine metabolism 1.287E–5 0.005
mRNA processing 3.887E–5 6.08E–06
Hedgehog signaling pathway 6.695E–4 0.005
Complement activation, classical pathway 0.002 0.003
Nucleotide metabolism 0.004 0.003
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Fig. 4 Relative mRNA expression of genes commonly deleted in human mesothelioma in mouse mesotheliomas as indicated. Genes investigated
were, NF2, BAP1, p16 and LATS2 and RB (inhibited by Sv40 TAg) and the cyclin dependent inhibitor p21, which has not been reported to be
dysregulated in mesothelioma
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finding that TAg causes the predictable changes in the
MexTAg tumours, the model can be reliably used ex-
perimentally to represent human disease, keeping TAg
effects in mind.
Some of the differentially expressed genes of interest
identified in the human study were also identified as
genes of interest in our mouse study, for example thymi-
dylate synthase and some of the tumour suppressor
genes. Furthermore, we found that the same pathways
were significantly altered in both species: including cell
cycle regulation, mitosis, DNA repair and apoptosis.
Thus, suggesting strong concordance of mesothelioma
development across species, to some extent irrespective
of TAg expression.
Of note, the MAP kinase pathway was significantly up-
regulated in the hiTAg mouse mesotheliomas compared
to the wild type mouse mesotheliomas, and consistent
with this the ras oncogene was also overexpressed in the
TAg tumours. While this could be a consequence of
large T antigen, activation of this particular cell signal-
ling cascade, has previously been associated with meso-
thelioma [27]. However, mutations in MAP kinase
pathway genes, including RAS and PIK3CA are very rare
in human mesothelioma [28].
Broad heterogeneity amongst human tumours is well
known and has been aligned with prognosis and re-
sponse to treatment. However, the steps in tumourigen-
esis that lead to this heterogeneity are only beginning to
be understood and could be a result of germline muta-
tions, somatic mutations, carcinogen exposure as well as
environmental and dietary factors. Thus, the heterogen-
eity amongst experimental mouse tumours would be
Fig. 5 Expression of E2F and E2F regulated genes in WT and MexTAg mesotheliomas and normal mesothelial samples derived from wild type or
transgenic mice. Validation quantitative PCRs were carried out using primers described in Methods and genes investigated are as indicated above
each graph
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expected to be somewhat less, due to their homogenous
genetic background and tightly regulated environment
and dietary intake. Despite this, heterogeneity is still evi-
dent in mouse tumour models that are carcinogen or
mutation induced [29, 30]. Individual tumours arising
from the same tumour cell line transplanted into a
group of mice, have related, but distinct gene expression
patterns [31]. Moreover, heterogeneity occurs within the
same tumour tissue [32].
In this study the method of induction was through a
standardised asbestos instillation and although there are
some significant differences in gene expression between
the TAg and non-TAg mesotheliomas, this is consistent
with differences found between cancers developing in
models not involving a foreign oncogene. Thus, the
MexTAg system can be used to further investigate meso-
thelioma development at the molecular level, taking into
account the known effects of TAg and the findings de-
scribed here.
Conclusion
Consistent with our previous observation that the patho-
genesis of MexTAg mesothelioma development closely
resembles human mesothelioma development, the data
presented here further validate the use of the MexTAg
model for investigating mesothelioma. In the context of
the existence of heterogeneity amongst individual tu-
mours arising from the same tumorigeneic process, we
consider the molecular differences described here be-
tween the transgenic and the wild type mesotheliomas
as small. Furthermore, the differences we identified fol-
low a pattern that is predictable given the presence of
the well-studied SV40 large T Antigen. The finding that
MexTAg tumours are not reliant on deletion of the
cdkN2 locus, suggests that this model could be useful in
further investigations of the sequence of molecular
events leading to mesothelioma after asbestos exposure.
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